Titan Pharmaceuticals, Inc. announced that the European Commission ("EC") has approved Sixmo®-buprenorphine, the brand name for Probuphine® (buprenorphine) implant in the European Union ("EU"). Probuphine was developed using ProNeura™, the continuous drug delivery system developed by Titan that consists of a small, solid implant made from a mixture of ethylene-vinyl acetate and a drug substance.